{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:49:03Z","timestamp":1790855343027,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU 01.945, TTU 01.709"],"award-info":[{"award-number":["TTU 01.945, TTU 01.709"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU 01.945, TTU 01.709"],"award-info":[{"award-number":["TTU 01.945, TTU 01.709"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1648\/1 2024-512741711"],"award-info":[{"award-number":["SFB 1648\/1 2024-512741711"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>MVA-MERS-S, a vaccine candidate against Middle East respiratory syndrome (MERS), was recently evaluated in a randomized, placebo-controlled, double-blind phase 1b clinical trial to assess its safety, immunogenicity, and optimal dosing in healthy adults in Hamburg and Rotterdam. A three-dose regimen was safe and elicited robust spike-specific antibody responses. We extended this trial to assess the two-year durability of MERS-CoV-specific antibody and T cell responses in 48 study participants of the Hamburg cohort. Our findings show that immune responses remain detectable for at least 24 months after the third vaccination. Antibodies persisted at levels comparable to the peak response observed after the second vaccination and were able to cross-neutralize MERS-CoV spike mutants. Although the immune correlates of protection against MERS remain unknown, the observed durability of humoral and cellular immune responses supports the potential of MVA-MERS-S as a promising MERS vaccine candidate and highlights the importance of a booster dose in sustaining long-term immunity.<\/jats:p>","DOI":"10.1038\/s41467-025-68248-5","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:35:29Z","timestamp":1767987329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Two-year persistence of MERS-CoV-specific antibody and T cell responses after MVA-MERS-S vaccination in healthy adults"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7102-4358","authenticated-orcid":false,"given":"Leonie","family":"Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8732-7085","authenticated-orcid":false,"given":"Hanna-Marie","family":"Weichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3774-8165","authenticated-orcid":false,"given":"Matthijs P.","family":"Raadsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Dahlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7188-6871","authenticated-orcid":false,"given":"Anna","family":"Mykytyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesche K.","family":"Gerresheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5361-4491","authenticated-orcid":false,"given":"Merel R.","family":"te Marvelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1175-7354","authenticated-orcid":false,"given":"Leonie M.","family":"Weskamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka","family":"Grewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Schlesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9468-7944","authenticated-orcid":false,"given":"Marc","family":"L\u00fctgehetmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7923-0519","authenticated-orcid":false,"given":"Christian","family":"Drosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6221-2015","authenticated-orcid":false,"given":"Bart L.","family":"Haagmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2913-9001","authenticated-orcid":false,"given":"Svenja","family":"Hardtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2836-9224","authenticated-orcid":false,"given":"Marylyn M.","family":"Addo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"68248_CR1","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","volume":"367","author":"AM Zaki","year":"2012","unstructured":"Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E. & Fouchier, R. A. M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814\u20131820 (2012).","journal-title":"N. Engl. J. Med."},{"key":"68248_CR2","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S0140-6736(19)33221-0","volume":"395","author":"ZA Memish","year":"2020","unstructured":"Memish, Z. A., Perlman, S., Kerkhove, M. D. V. & Zumla, A. Middle East respiratory syndrome. Lancet 395, 1063\u20131077 (2020).","journal-title":"Lancet"},{"key":"68248_CR3","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0140-6736(24)00641-X","volume":"403","author":"A Zumla","year":"2024","unstructured":"Zumla, A., Peiris, M., Memish, Z. A. & Perlman, S. Anticipating a MERS-like coronavirus as a potential pandemic threat. Lancet 403, 1729\u20131731 (2024).","journal-title":"Lancet"},{"key":"68248_CR4","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1473-3099(20)30248-6","volume":"20","author":"T Koch","year":"2020","unstructured":"Koch, T. et al. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infect. Dis. 20, 827\u2013838 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"68248_CR5","doi-asserted-by":"publisher","first-page":"100685","DOI":"10.1016\/j.xcrm.2022.100685","volume":"3","author":"LM Weskamm","year":"2022","unstructured":"Weskamm, L. M. et al. Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine. Cell Rep. Med. 3, 100685 (2022).","journal-title":"Cell Rep. Med."},{"key":"68248_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31557-0","volume":"13","author":"A Fathi","year":"2022","unstructured":"Fathi, A. et al. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome. Nat. Commun. 13, 4182 (2022).","journal-title":"Nat. Commun."},{"key":"68248_CR7","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S2666-5247(21)00193-2","volume":"3","author":"M Bosaeed","year":"2022","unstructured":"Bosaeed, M. et al. Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. Lancet Microbe 3, e11\u2013e20 (2022).","journal-title":"Lancet Microbe"},{"key":"68248_CR8","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","volume":"20","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect. Dis. 20, 816\u2013826 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"68248_CR9","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","volume":"19","author":"K Modjarrad","year":"2019","unstructured":"Modjarrad, K. et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect. Dis. 19, 1013\u20131022 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"68248_CR10","doi-asserted-by":"crossref","unstructured":"Raadsen, M. P. et al. Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial. Lancet Infect. Dis. 25, 231\u2013242 (2024).","DOI":"10.2139\/ssrn.4802678"},{"key":"68248_CR11","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"68248_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"68248_CR13","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903\u20131915 (2007).","journal-title":"N. Engl. J. Med."},{"key":"68248_CR14","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.immuni.2022.05.004","volume":"55","author":"D Bhattacharya","year":"2022","unstructured":"Bhattacharya, D. Instructing durable humoral immunity for COVID-19 and other vaccinable diseases. Immunity 55, 945\u2013964 (2022).","journal-title":"Immunity"},{"key":"68248_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","volume":"57","author":"K Srivastava","year":"2024","unstructured":"Srivastava, K. et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. Immunity 57, 587\u2013599.e4 (2024).","journal-title":"Immunity"},{"key":"68248_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jama.2021.22898","volume":"327","author":"TA Bates","year":"2022","unstructured":"Bates, T. A. et al. Antibody response and variant cross-neutralization after SARS-CoV-2 breakthrough infection. JAMA 327, 179\u2013181 (2022).","journal-title":"JAMA"},{"key":"68248_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39816-4","volume":"14","author":"T Hertz","year":"2023","unstructured":"Hertz, T. et al. Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2. Nat. Commun. 14, 4575 (2023).","journal-title":"Nat. Commun."},{"key":"68248_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S2213-2600(23)00015-2","volume":"11","author":"N Wu","year":"2023","unstructured":"Wu, N. et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir. Med. 11, 439\u2013452 (2023).","journal-title":"Lancet Respir. Med."},{"key":"68248_CR19","doi-asserted-by":"publisher","unstructured":"Raadsen, M. P. et al. Brief report: monkeypox virus cross-neutralizing antibodies in clinical trial subjects vaccinated with modified vaccinia virus Ankara encoding MERS-Coronavirus spike protein. J. Infect. Dis. jiad052 https:\/\/doi.org\/10.1093\/infdis\/jiad052 (2023).","DOI":"10.1093\/infdis\/jiad052"},{"key":"68248_CR20","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1016\/j.vaccine.2017.05.032","volume":"35","author":"NK Alharbi","year":"2017","unstructured":"Alharbi, N. K. et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine 35, 3780\u20133788 (2017).","journal-title":"Vaccine"},{"key":"68248_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41577-019-0244-2","volume":"20","author":"M Akkaya","year":"2020","unstructured":"Akkaya, M., Kwak, K. & Pierce, S. K. B cell memory: building two walls of protection against pathogens. Nat. Rev. Immunol. 20, 229\u2013238 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"68248_CR22","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","volume":"385","author":"YM Bar-On","year":"2021","unstructured":"Bar-On, Y. M. et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N. Engl. J. Med. 385, 1393\u20131400 (2021).","journal-title":"N. Engl. J. Med."},{"key":"68248_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2174779","volume":"12","author":"P Sritipsukho","year":"2023","unstructured":"Sritipsukho, P. et al. Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need? Emerg. Microbes Infect. 12, 2174779 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"68248_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","volume":"185","author":"WF Garcia-Beltran","year":"2022","unstructured":"Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457\u2013466.e4 (2022).","journal-title":"Cell"},{"key":"68248_CR25","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.cmi.2023.08.026","volume":"29","author":"A Huttner","year":"2023","unstructured":"Huttner, A. et al. Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability. Clin. Microbiol. Infect. 29, 1587\u20131594 (2023).","journal-title":"Clin. Microbiol. Infect."},{"key":"68248_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1182\/blood-2016-07-729756","volume":"129","author":"C La Rosa","year":"2017","unstructured":"La Rosa, C. et al. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. Blood 129, 114\u2013125 (2017).","journal-title":"Blood"},{"key":"68248_CR27","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","volume":"14","author":"JHCM Kreijtz","year":"2014","unstructured":"Kreijtz, J. H. C. M. et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial. Lancet Infect. Dis. 14, 1196\u20131207 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"68248_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","volume":"27","author":"JR Barrett","year":"2021","unstructured":"Barrett, J. R. et al. Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat. Med. 27, 279\u2013288 (2021).","journal-title":"Nat. Med."},{"key":"68248_CR29","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1038\/s41590-022-01361-5","volume":"23","author":"I Pedroza-Pacheco","year":"2022","unstructured":"Pedroza-Pacheco, I. & McMichael, A. J. Immune signature atlas of vaccines: learning from the good responders. Nat. Immunol. 23, 1654\u20131656 (2022).","journal-title":"Nat. Immunol."},{"key":"68248_CR30","doi-asserted-by":"publisher","first-page":"199156","DOI":"10.1016\/j.virusres.2023.199156","volume":"334","author":"W Tai","year":"2023","unstructured":"Tai, W. et al. MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection. Virus Res. 334, 199156 (2023).","journal-title":"Virus Res."},{"key":"68248_CR31","doi-asserted-by":"publisher","first-page":"6117","DOI":"10.1128\/JVI.00446-15","volume":"89","author":"J Zhao","year":"2015","unstructured":"Zhao, J. et al. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. J. Virol. 89, 6117\u20136120 (2015).","journal-title":"J. Virol."},{"key":"68248_CR32","doi-asserted-by":"publisher","first-page":"e0232790","DOI":"10.1371\/journal.pone.0232790","volume":"15","author":"AM Tolah","year":"2020","unstructured":"Tolah, A. M. et al. Cross-sectional prevalence study of MERS-CoV in local and imported dromedary camels in Saudi Arabia, 2016-2018. PloS One 15, e0232790 (2020).","journal-title":"PloS One"},{"key":"68248_CR33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.cmi.2021.06.009","volume":"28","author":"S Cheon","year":"2022","unstructured":"Cheon, S. et al. Longevity of seropositivity and neutralizing antibodies in recovered MERS patients: a 5-year follow-up study. Clin. Microbiol. Infect. 28, 292\u2013296 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"68248_CR34","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3201\/eid2506.181722","volume":"25","author":"Y-S Kim","year":"2019","unstructured":"Kim, Y.-S. et al. Sequential emergence and wide spread of neutralization escape Middle East respiratory syndrome coronavirus mutants, South Korea, 2015. Emerg. Infect. Dis. 25, 1161 (2019).","journal-title":"Emerg. Infect. Dis."},{"key":"68248_CR35","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3201\/eid2506.181722","volume":"25","author":"Y-S Kim","year":"2019","unstructured":"Kim, Y.-S. et al. Sequential emergence and wide spread of neutralization escape Middle East respiratory syndrome coronavirus mutants, South Korea, 2015. Emerg. Infect. Dis. 25, 1161\u20131168 (2019).","journal-title":"Emerg. Infect. Dis."},{"key":"68248_CR36","doi-asserted-by":"publisher","first-page":"e01381","DOI":"10.1128\/JVI.01381-18","volume":"93","author":"H Kleine-Weber","year":"2019","unstructured":"Kleine-Weber, H. et al. Mutations in the spike protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization. J. Virol. 93, e01381\u201318 (2019).","journal-title":"J. Virol."},{"key":"68248_CR37","doi-asserted-by":"crossref","unstructured":"Addetia, A. et al. Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans. Cell Rep. 43, 114530 (2024).","DOI":"10.1016\/j.celrep.2024.114530"},{"key":"68248_CR38","doi-asserted-by":"publisher","unstructured":"Kleine-Weber, H. et al. Mutations in the spike protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization. J. Virol. 93, https:\/\/doi.org\/10.1128\/jvi.01381-18 (2019).","DOI":"10.1128\/jvi.01381-18"},{"key":"68248_CR39","first-page":"00804","volume":"S0092-8674","author":"TA Pereira Neto","year":"2025","unstructured":"Pereira Neto, T. A. et al. Highly conserved Betacoronavirus sequences are broadly recognized by human T cells. Cell S0092-8674, 00804\u201300809 (2025).","journal-title":"Cell"},{"key":"68248_CR40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1146\/annurev-immunol-101721-061120","volume":"41","author":"A Sette","year":"2023","unstructured":"Sette, A., Sidney, J. & Crotty, S. T cell responses to SARS-CoV-2. Annu. Rev. Immunol. 41, 343\u2013373 (2023).","journal-title":"Annu. Rev. Immunol."},{"key":"68248_CR41","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","volume":"23","author":"P Moss","year":"2022","unstructured":"Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23, 186\u2013193 (2022).","journal-title":"Nat. Immunol."},{"key":"68248_CR42","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41577-022-00809-x","volume":"23","author":"SM Murray","year":"2023","unstructured":"Murray, S. M. et al. The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. Nat. Rev. Immunol. 23, 304\u2013316 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"68248_CR43","first-page":"00804","volume":"S0092-8674","author":"TAP Neto","year":"2025","unstructured":"Neto, T. A. P. et al. Highly conserved Betacoronavirus sequences are broadly recognized by human T cells. Cell S0092-8674, 00804\u201300809 (2025).","journal-title":"Cell"},{"key":"68248_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s43588-022-00198-0","volume":"2","author":"P Padmanabhan","year":"2022","unstructured":"Padmanabhan, P., Desikan, R. & Dixit, N. M. Modeling how antibody responses may determine the efficacy of COVID-19 vaccines. Nat. Comput. Sci. 2, 123\u2013131 (2022).","journal-title":"Nat. Comput. Sci."},{"key":"68248_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-024-00872-6","volume":"9","author":"DF King","year":"2024","unstructured":"King, D. F. et al. Realising the potential of correlates of protection for vaccine development, licensure and use: short summary. Npj Vaccines 9, 1\u20139 (2024).","journal-title":"Npj Vaccines"},{"key":"68248_CR46","unstructured":"MERS-CoV worldwide overview, situation update, 5 February 2025. European Center for Disease Prevention and Control https:\/\/www.ecdc.europa.eu\/en\/middle-east-respiratory-syndrome-coronavirus-mers-cov-situation-update (2025)."},{"key":"68248_CR47","unstructured":"Mattiuzzo, G., Bentley, E., & Seo, S. H. WHO\/BS\/2020.2398 Establishment of 1st WHO International Standard for Anti-MERS-CoV AntibodyGiada (WHO, 2020)."},{"key":"68248_CR48","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.64508","volume":"10","author":"AZ Mykytyn","year":"2021","unstructured":"Mykytyn, A. Z. et al. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site. eLife 10, e64508 (2021).","journal-title":"eLife"},{"key":"68248_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25519-1","volume":"12","author":"S Schroeder","year":"2021","unstructured":"Schroeder, S. et al. Functional comparison of MERS-coronavirus lineages reveals increased replicative fitness of the recombinant lineage 5. Nat. Commun. 12, 5324 (2021).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68248-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68248-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68248-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:02:06Z","timestamp":1768370526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68248-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68248"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-68248-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.F. became a full-time employee of BioNTech in January, 2024, after completion of her contribution to this study. C. Dahlke was recruited as the translational immunology lead at the Coalition for Epidemic Preparedness Innovations (CEPI) in November, 2022, with responsibilities separate from her role in the present study. B.L.H. is an inventor on a MERS patent with Erasmus MC Rotterdam (No. WO2014045254 A3). S.B. is named as an inventor on a patent for a novel MERS-CoV vaccine (No. EP3045181A1). All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"480"}}